Free Trial

InterCure (NASDAQ:INCR) Stock Price Up 2.1% - Still a Buy?

InterCure logo with Medical background

Key Points

  • InterCure Ltd. (NASDAQ:INCR) shares saw a price increase of 2.1%, closing at $1.49 after a peak of $1.50.
  • The company has seen a recent investment from Moore Capital Management LP, which purchased 97,273 shares valued at approximately $156,000.
  • InterCure specializes in the research, cultivation, and distribution of pharmaceutical-grade cannabis products for medical use, both in Israel and internationally.
  • Looking to export and analyze InterCure data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

InterCure Ltd. (NASDAQ:INCR - Get Free Report)'s stock price shot up 2.1% during trading on Thursday . The stock traded as high as $1.50 and last traded at $1.49. 34,365 shares changed hands during trading, a decline of 3% from the average session volume of 35,331 shares. The stock had previously closed at $1.46.

InterCure Price Performance

The company has a debt-to-equity ratio of 0.34, a current ratio of 1.73 and a quick ratio of 1.18. The business has a fifty day moving average of $1.51 and a 200-day moving average of $1.52.

Institutional Trading of InterCure

A hedge fund recently bought a new stake in InterCure stock. Moore Capital Management LP acquired a new position in InterCure Ltd. (NASDAQ:INCR - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 97,273 shares of the company's stock, valued at approximately $156,000. Moore Capital Management LP owned 0.21% of InterCure as of its most recent filing with the Securities and Exchange Commission (SEC). 8.34% of the stock is currently owned by hedge funds and other institutional investors.

About InterCure

(Get Free Report)

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.

Recommended Stories

Should You Invest $1,000 in InterCure Right Now?

Before you consider InterCure, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InterCure wasn't on the list.

While InterCure currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

$15 Billion for Cybersecurity: The Government’s Next Big Push
Tesla’s Future Unleashed: Elon’s Robotics Move Changes Everything
Top Trades: Massive Gains and Costly Mistakes to Avoid

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines